Thoracoscopy (VATS) for Mesothelioma

Thoracoscopy, also known as video-assisted thoracoscopic surgery (VATS), is a minimally invasive procedure that allows direct visual examination of the pleural cavity and biopsy of the pleural surfaces. It is the primary diagnostic and staging tool for malignant pleural mesothelioma, providing the large tissue samples needed for accurate histological diagnosis while simultaneously enabling assessment of tumor extent to guide treatment planning. When mesothelioma is suspected, thoracoscopy is typically the procedure that confirms the diagnosis.¹

During the procedure, a rigid or flexible endoscope with an attached camera (thoracoscope) is inserted through a small incision in the chest wall, typically 1 to 2 centimeters in length. One or two additional small incisions may be made for instruments. The camera transmits magnified high-definition images of the pleural surfaces to a video monitor, allowing the surgeon to visualize the parietal pleura, visceral pleura, diaphragm, and mediastinum in detail. Suspicious areas are biopsied under direct vision, providing tissue specimens that are substantially larger and more diagnostically reliable than those obtained by CT-guided needle biopsy.²

A major advantage of thoracoscopy in mesothelioma evaluation is that it combines diagnostic biopsy with therapeutic intervention in a single procedure. If a pleural effusion is present, it can be drained completely during thoracoscopy. Furthermore, talc pleurodesis — the instillation of sterile talc powder onto the pleural surfaces to prevent fluid reaccumulation — can be performed during the same session, sparing the patient a separate procedure. This "diagnose and treat" capability makes thoracoscopy exceptionally efficient for the initial management of suspected mesothelioma.³

Thoracoscopy exists in two forms: surgical VATS, performed by a thoracic surgeon under general anesthesia in the operating room, and medical thoracoscopy (also called pleuroscopy), performed by a pulmonologist under local anesthesia with conscious sedation in an endoscopy suite. Both approaches provide excellent diagnostic accuracy for mesothelioma (>90%), though surgical VATS allows for more extensive exploration and biopsy when aggressive staging is needed to plan cytoreductive surgery.⁴

Thoracoscopy for mesothelioma evaluation is performed in two primary settings:⁴

• Surgical VATS (video-assisted thoracoscopic surgery) — Performed by a thoracic surgeon under general anesthesia with single-lung ventilation. Uses rigid trocars and instruments through 2–3 ports. Provides the most comprehensive visualization and largest tissue specimens. Preferred when extensive staging is needed or when cytoreductive surgery (P/D or EPP) is being considered, as the surgeon can assess resectability during the procedure.²
• Medical thoracoscopy (pleuroscopy) — Performed by a pulmonologist or interventional physician under local anesthesia with conscious sedation. Uses a semi-rigid or rigid pleuroscope through a single port. Can be performed in an endoscopy suite rather than an operating room. Diagnostic accuracy is comparable to surgical VATS for pleural malignancy. Preferred for patients who are poor surgical candidates or when the primary goal is diagnostic biopsy with effusion management.⁴

Thoracoscopy is not a disease and does not cause symptoms. However, the clinical presentations that lead to thoracoscopy for mesothelioma evaluation include:¹

• Unexplained pleural effusion — Fluid accumulation between the lung and chest wall is the most common presenting finding in pleural mesothelioma, occurring in approximately 90% of patients at diagnosis
• Progressive dyspnea from effusion or tumor encasement of the lung
• Chest pain that may be pleuritic or constant
• Pleural thickening detected on CT imaging
• Non-diagnostic pleural fluid cytology — When thoracentesis (needle drainage) obtains fluid but cytological examination cannot confirm or exclude mesothelioma, thoracoscopy is the next step
• Non-diagnostic CT-guided needle biopsy — Small needle biopsy specimens may be insufficient for definitive mesothelioma diagnosis, which requires immunohistochemical staining on adequate tissue

After thoracoscopy, patients may experience mild chest pain at the port sites, temporary shortness of breath, and minor discomfort from the chest tube that is typically left in place for 1 to 3 days. These symptoms resolve quickly, and most patients are discharged within 1 to 3 days.³

Thoracoscopy is itself a diagnostic procedure — the gold standard for diagnosing pleural mesothelioma. Its diagnostic capabilities include:²

• Direct visualization — The thoracoscope provides a magnified, high-definition view of the entire pleural cavity. Mesothelioma typically appears as multiple white, nodular, or plaque-like deposits on the parietal pleura, often with a "grape-like" clustering pattern. The surgeon can assess the extent of disease across the parietal pleura, visceral pleura, diaphragm, and mediastinum.²
• Directed biopsy — Multiple biopsies are taken under direct vision from the most suspicious areas, providing large tissue specimens (typically 5–10 mm each) that are sufficient for comprehensive histological analysis. This is a critical advantage over needle biopsy, which yields small cores that may not contain enough tissue for the immunohistochemical panel needed to confirm mesothelioma and distinguish it from adenocarcinoma.¹
• Histological subtyping — Adequate tissue from thoracoscopic biopsy allows pathologists to determine mesothelioma subtype (epithelioid, sarcomatoid, or biphasic), which is essential for prognosis and treatment planning.¹
• Staging assessment — Thoracoscopy enables visual assessment of T-stage (tumor extent), including involvement of the diaphragm, pericardium, and chest wall. This information helps determine whether a patient is a candidate for cytoreductive surgery.²
• Diagnostic accuracy — Thoracoscopy has a diagnostic sensitivity exceeding 90% for pleural mesothelioma, significantly higher than CT-guided needle biopsy (approximately 60–80%) or pleural fluid cytology (approximately 30–50%).⁴

While primarily a diagnostic procedure, thoracoscopy has important therapeutic applications in mesothelioma management:³

• Complete effusion drainage — Thoracoscopy allows drainage of the entire pleural effusion under direct vision, providing immediate relief of dyspnea. Unlike needle thoracentesis, which may leave loculated fluid pockets, thoracoscopy enables adhesion lysis and complete evacuation.³
• Talc pleurodesis — Sterile talc powder is insufflated (sprayed) across the pleural surfaces during thoracoscopy, creating an inflammatory reaction that fuses the visceral and parietal pleura together and prevents fluid reaccumulation. Thoracoscopic talc pleurodesis has a success rate of 70–90% for malignant pleural effusions and can be performed during the same procedure as diagnostic biopsy.³
• Indwelling pleural catheter placement — For patients in whom pleurodesis fails or is not appropriate, a tunneled pleural catheter can be placed during or after thoracoscopy for ongoing outpatient drainage.³
• Resectability assessment — During thoracoscopy, the surgeon can assess whether complete cytoreductive surgery (P/D or EPP) is feasible, evaluating tumor extent, chest wall invasion, and diaphragmatic involvement to inform subsequent surgical planning.²

Procedure details:

• Duration: 30 to 90 minutes depending on extent of biopsy and whether pleurodesis is performed
• Incisions: 2–3 small ports, each 1–2 cm in length
• Chest tube: Placed at the end of the procedure and typically removed in 1–3 days
• Hospital stay: 1–3 days for surgical VATS; same-day or overnight for medical thoracoscopy
• Recovery: Most patients return to normal activities within 1–2 weeks

Complications (uncommon):

• Persistent air leak (3–5%)
• Port-site tumor seeding (5–10% without prophylactic radiation, reducible with port-site irradiation)
• Subcutaneous emphysema
• Bleeding requiring intervention (rare, <1%)
• Infection or empyema (rare)

Thoracoscopy itself does not determine prognosis, but the information it provides is critical for prognosis assessment. The histological subtype identified by thoracoscopic biopsy is one of the most important prognostic factors in mesothelioma: epithelioid histology carries the best prognosis (median survival 14–20 months), biphasic is intermediate (10–14 months), and sarcomatoid has the poorest outlook (4–8 months).¹

The visual staging assessment performed during thoracoscopy also provides important prognostic information. Patients with limited, resectable disease identified at thoracoscopy have a better prognosis than those with extensive, unresectable tumor involvement. Early thoracoscopic diagnosis — before disease becomes advanced — enables patients to access the full range of treatment options, including potentially curative cytoreductive surgery, which offers the best chance of extended survival.²